Back to Search Start Over

Association of APOE-Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults

Authors :
Xicota, Laura
Gyorgy, Beata
Grenier-Boley, Benjamin
Lecoeur, Alexandre
Fontaine, Gaelle
Danjou, Fabrice
Gonzalez, Jorge Samper
Colliot, Olivier
Amouyel, Philippe
Martin, Garance
Levy, Marcel
Villain, Nicolas
Habert, Marie-Odile
Dubois, Bruno
Lambert, Jean-Charles
Potier, Marie-Claude
Institut du Cerveau = Paris Brain Institute (ICM)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)
CHU Lille
Algorithms, models and methods for images and signals of the human brain (ARAMIS)
Sorbonne Université (SU)-Inria de Paris
Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Institut du Cerveau = Paris Brain Institute (ICM)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)
Centre d'Acquisition et de Traitement des Images [Paris]
Commissariat à l'énergie atomique et aux énergies alternatives (CEA)
Institut de la Mémoire et de la Maladie d'Alzheimer [CHU Pitié-Salpétriêre] (IM2A)
CHU Pitié-Salpêtrière [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
This research was funded by the French government under management of Agence Nationale de la Recherche as part of the 'Investissements d'avenir' program (ANR-10-AIHU-06), ANR-19-P3IA-0001 (PRAIRIE 3IA Institute), the INSERM, Institut Pasteur de Lille, the Lille Métropole Communauté Urbaine and the French government’s LABEX DISTALZ program (development of innovative strategies for a transdisciplinary approach to Alzheimer’s disease). LX was supported by a fellowship from Institut de Recherche Servier.
ANR-19-P3IA-0001,PRAIRIE,PaRis Artificial Intelligence Research InstitutE(2019)
Colliot, Olivier
PaRis Artificial Intelligence Research InstitutE - - PRAIRIE2019 - ANR-19-P3IA-0001 - P3IA - VALID
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Source :
Neurology, Neurology, In press, 99 (5), pp.10.1212/WNL.0000000000200544. ⟨10.1212/WNL.0000000000200544⟩, Neurology, inPress, 99 (5), pp.10.1212/WNL.0000000000200544. ⟨10.1212/WNL.0000000000200544⟩
Publication Year :
2022
Publisher :
HAL CCSD, 2022.

Abstract

Background and ObjectivesBrain amyloid deposition, a major risk factor for Alzheimer disease (AD), is currently estimated by measuring CSF or plasma amyloid peptide levels or by PET imaging. Assessing genetic risks relating to amyloid deposition before any accumulation has occurred would allow for earlier intervention in persons at increased risk for developing AD. Previous work linking amyloid burden and genetic risk relied almost exclusively on APOE, a major AD genetic risk factor. Here, we ask whether a polygenic risk score (PRS) that incorporates an optimized list of common variants linked to AD and excludes APOE is associated with brain amyloid load in cognitively unimpaired older adults.MethodsWe included 291 asymptomatic older participants from the INveStIGation of AlzHeimer's PredicTors (INSIGHT pre-AD) cohort who underwent amyloid imaging, including 83 amyloid-positive (+) participants. We used an Alzheimer's (A) PRS composed of 33 AD risk variants excluding APOE and selected the 17 variants that showed the strongest association with amyloid positivity to define an optimized (oA) PRS. Participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) study (228 participants, 90 amyloid [+]) were tested as a validation cohort. Finally, 2,300 patients with AD and 6,994 controls from the European Alzheimer's Disease Initiative (EADI) were evaluated.ResultsA-PRS was not significantly associated with amyloid burden in the INSIGHT or ADNI cohorts with or without correction for the APOE genotype. However, oA-PRS was significantly associated with amyloid status independently of APOE adjustment (INSIGHT odds ratio [OR]: 5.26 [1.71–16.88]; ADNI OR: 3.38 [1.02–11.63]). Of interest, oA-PRS accurately discriminated amyloid (+) and (−) APOE ε4 carriers (INSIGHT OR: 181.6 [7.53–10,674.6]; ADNI OR: 44.94 [3.03–1,277]). A-PRS and oA-PRS showed a significant association with disease status in the EADI cohort (OR: 1.68 [1.53–1.85] and 2.06 [1.73–2.45], respectively). Genes assigned to oA-PRS variants were enriched in ontologies related to β-amyloid metabolism and deposition.DiscussionPRSs relying on AD genetic risk factors excluding APOE may improve risk prediction for brain amyloid, allowing stratification of cognitively unimpaired individuals at risk of AD independent of their APOE status.

Details

Language :
English
ISSN :
00283878 and 1526632X
Database :
OpenAIRE
Journal :
Neurology, Neurology, In press, 99 (5), pp.10.1212/WNL.0000000000200544. ⟨10.1212/WNL.0000000000200544⟩, Neurology, inPress, 99 (5), pp.10.1212/WNL.0000000000200544. ⟨10.1212/WNL.0000000000200544⟩
Accession number :
edsair.doi.dedup.....0be1b619a035fe1db8b3abdfbdeb4aa1
Full Text :
https://doi.org/10.1212/WNL.0000000000200544.